DISEASE SCANNER
Global Incurable Diseases Tracker
Non-Alcoholic Steatohepatitis
The progressive form of non-alcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis with inflammation and hepatocyte injury, with or without fibrosis. Can progress to cirrhosis and hepatocellular carcinoma. Now called MASH (metabolic dysfunction-associated steatohepatitis).
115.0M
111
Symptoms
Treatment Options
Risk Factors
Diagnostic Methods
- 1Liver enzymes (ALT, AST)
- 2Liver ultrasound
- 3FibroScan (elastography)
- 4MRI-PDFF (steatosis quantification)
- 5Liver biopsy (gold standard)
- 6FIB-4 or NAFLD fibrosis score
- 7Magnetic resonance elastography
- 8Assessment for metabolic syndrome
Prognosis
20-30% progress to cirrhosis over 10-20 years. Leading indication for liver transplant in US. Cardiovascular disease leading cause of death. HCC risk increased. With weight loss and new therapies, fibrosis can regress.
Prevention
- Weight management
- Healthy diet (Mediterranean)
- Regular exercise
- Diabetes prevention/control
- Limit alcohol
- Avoid fructose-sweetened beverages
- Regular screening in at-risk
Research Status
Resmetirom (THR-β agonist) first FDA-approved treatment March 2024. GLP-1 agonists (semaglutide) showing significant benefit. Pioglitazone and vitamin E (non-diabetics). FGF21 analogs in trials. Obeticholic acid (FXR agonist) had issues. Bariatric surgery effective.
Affected Countries
Sources
- https://liverfoundation.org
- https://www.cdc.gov/
- https://www.hematology.org/education/patients
- https://www.ncbi.nlm.nih.gov/books
- https://rarediseases.org/rare-diseases
Medical Disclaimer
This information is for educational purposes only. Always consult healthcare professionals for medical advice, diagnosis, and treatment.